{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:04:40Z","timestamp":1784880280375,"version":"3.55.0"},"reference-count":42,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Secondary pelvic cancer (SC) risk after radiotherapy (RT) for prostate cancer (PC) remains uncertain; we performed an updated synthesis of observational studies and randomized trials. Methods: We reviewed systematic reviews, meta-analyses, and randomized trials published in 2001\u20132025 evaluating SC risk after RT for PC. Given potential detection bias from RT-related rectal or bladder bleeding, the primary outcome was relative risk (RR) of death. Results: Across 12 reports\u2014eight systematic reviews\/meta-analyses and four randomized trials\u2014comparators were predominantly RP or mixed cohorts; review-level sample sizes were not summed because of potential overlap. In randomized data with &gt;10 years of follow-up, SC occurred in 25.3% of RT-treated patients versus 20.8% in RP\/hormone therapy groups, while deaths from other cancers occurred in 8.5% versus 7.2%. The median converted RR of death from SC was 1.05. These estimates may be influenced by unmeasured lifestyle factors such as smoking and baseline comorbidities, which were not accounted for in observational cohorts and are more common among patients receiving RT, who are often less likely to be RP candidates. Conclusions: RT is associated with a small but consistent increase in SC, with a 4.5% absolute excess incidence over &gt;10 years. The observed 1.3% absolute difference in deaths from other cancers was modest and similar in magnitude to the reported perioperative mortality range of approximately 0.2\u20131.1% after RP, although these risks occur over substantially different time horizons. The smaller excess seen in randomized trials than in retrospective studies suggests that much of the apparent risk in prior reports may reflect confounding and\/or detection bias rather than direct radiation effect.<\/jats:p>","DOI":"10.3390\/cancers18152382","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:36:13Z","timestamp":1784878573000},"page":"2382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Secondary Pelvic Cancers Following Radiotherapy for Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-0951","authenticated-orcid":false,"given":"Mutlay","family":"Sayan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital,  Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-3233","authenticated-orcid":false,"given":"Yetkin","family":"Tuac","sequence":"additional","affiliation":[{"name":"Department of Statistics, Ankara University, Ankara 06100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-4975","authenticated-orcid":false,"given":"Yun Rose","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-7994","authenticated-orcid":false,"given":"Pamela W.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Division of Urology, Howard University College of Medicine, Washington, DC 20059, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Mack","family":"Roach","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijrobp.2009.02.011","article-title":"The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: A population-based study on 17,845 patients","volume":"76","author":"Bhojani","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bagshaw, H.P., Arnow, K.D., Trickey, A.W., Leppert, J.T., Wren, S.M., and Morris, A.M. (2022). Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs. Surgery for the Treatment of Prostate Cancer. JAMA Netw. Open, 5.","DOI":"10.1001\/jamanetworkopen.2022.23025"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/UPJ.0000000000000479","article-title":"Risk and Prognostics of Second Primary Cancer After Prostate Radiation Therapy","volume":"11","author":"Liu","year":"2024","journal-title":"Urol. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.juro.2012.04.109","article-title":"Causes of death after radical prostatectomy at a large tertiary center","volume":"188","author":"Eifler","year":"2012","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"Jama"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.51936\/uwah2960","article-title":"Odds Ratio, Hazard Ratio and Relative Risk","volume":"13","author":"Stare","year":"2016","journal-title":"Adv. Methodol. Stat."},{"key":"ref_8","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program (2025, August 09). Cancer Stat Facts: Colorectal Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html."},{"key":"ref_9","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program (2025, August 09). SEER Cancer Stat Facts: Bladder Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique","volume":"110","author":"Murray","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000356115","article-title":"Radiation-induced secondary malignancy in prostate cancer: A systematic review and meta-analysis","volume":"93","author":"Jin","year":"2014","journal-title":"Urol. Int."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wallis, C.J., Mahar, A.L., Choo, R., Herschorn, S., Kodama, R.T., Shah, P.S., Danjoux, C., Narod, S.A., and Nam, R.K. (2016). Second malignancies after radiotherapy for prostate cancer: Systematic review and meta-analysis. BMJ, 352.","DOI":"10.1136\/bmj.i851"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00268-015-3324-x","article-title":"Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer","volume":"40","author":"Lee","year":"2016","journal-title":"World J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00384-018-3114-7","article-title":"Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: A meta-analysis","volume":"33","author":"Zhu","year":"2018","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctrv.2018.05.008","article-title":"Does pelvic radiation increase rectal cancer incidence?\u2014A systematic review and meta-analysis","volume":"68","author":"Rombouts","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00384-021-04075-6","article-title":"Prostate radiotherapy and the risk of secondary rectal cancer\u2014A meta-analysis","volume":"37","author":"Nugent","year":"2022","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.euf.2024.12.003","article-title":"Incidence and Outcomes of Secondary Bladder Cancer Following Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"11","author":"Matsukawa","year":"2025","journal-title":"Eur. Urol. Focus."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijrobp.2019.11.027","article-title":"Second Cancers in Patients with Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment with or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial","volume":"106","author":"Myklebust","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jnci\/dji313","article-title":"30-day mortality and major complications after radical prostatectomy: Influence of age and comorbidity","volume":"97","author":"Alibhai","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.5489\/cuaj.749","article-title":"Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy","volume":"8","author":"Hansen","year":"2014","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_24","first-page":"157.e7","article-title":"The association of age with perioperative morbidity and mortality among men undergoing radical prostatectomy","volume":"36","author":"Pereira","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41391-018-0051-z","article-title":"The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: Analysis of the National Surgical Quality Improvement Program (NSQIP)","volume":"21","author":"Brito","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bju.13404","article-title":"Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: A nationwide population-based study","volume":"118","author":"Folkvaljon","year":"2016","journal-title":"BJU Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1464-410X.2007.07373.x","article-title":"The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: A population-based analysis of 9208 consecutive cases","volume":"101","author":"Walz","year":"2008","journal-title":"BJU Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/01.ju.0000158163.21079.66","article-title":"Variations among high volume surgeons in the rate of complications after radical prostatectomy: Further evidence that technique matters","volume":"173","author":"Bianco","year":"2005","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.eururo.2004.12.010","article-title":"Reoperation, Myocardial Infarction and Mortality after Transurethral and Open Prostatectomy: A Nation-Wide, Long-Term Analysis of 23,123 Cases","volume":"47","author":"Madersbacher","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00345-022-03999-0","article-title":"Mortality after surgery for benign prostate hyperplasia: A nationwide cohort study","volume":"40","author":"Salmivalli","year":"2022","journal-title":"World J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10654-016-0138-6","article-title":"Modifiable risk factors for the prevention of bladder cancer: A systematic review of meta-analyses","volume":"31","author":"Stewart","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"ref_33","first-page":"4787","article-title":"Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer","volume":"57","author":"Wilkens","year":"1997","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.24343","article-title":"The impact of dietary and lifestyle risk factors on risk of colorectal cancer: A quantitative overview of the epidemiological evidence","volume":"125","author":"Huxley","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology\/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zaorsky, N.G., Proudfoot, J.A., Jia, A.Y., Zuhour, R., Vince, R., Liu, Y., Zhao, X., Hu, J., Schussler, N.C., and Stevens, J.L. (2023). Use of the Decipher genomic classifier among men with prostate cancer in the United States. JNCI Cancer Spectr., 7.","DOI":"10.1093\/jncics\/pkad052"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Esteva, A., Feng, J., van der Wal, D., Huang, S.C., Simko, J.P., DeVries, S., Chen, E., Schaeffer, E.M., Morgan, T.M., and Sun, Y. (2023). Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. npj Digit. Med., 6.","DOI":"10.1038\/s41746-023-00769-z"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Spratt, D.E., Tang, S., Sun, Y., Huang, H.C., Chen, E., Mohamad, O., Armstrong, A.J., Tward, J.D., Nguyen, P.L., and Lang, J.M. (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid., 2.","DOI":"10.1056\/EVIDoa2300023"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-05-2703","article-title":"Association of DNA Repair and Steroid Metabolism Gene Polymorphisms with Clinical Late Toxicity in Patients Treated with Conformal Radiotherapy for Prostate Cancer","volume":"12","author":"Damaraju","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.semradonc.2015.05.006","article-title":"The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention","volume":"25","author":"Kerns","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/j.ijrobp.2023.06.1528","article-title":"Prospective Validation of Single Nucleotide Polymorphisms as Predictors of Gastrointestinal, Genitourinary, and Sexual Patient-Reported Outcomes Following Radiotherapy for Prostate Cancer","volume":"117","author":"Kamran","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:45:47Z","timestamp":1784879147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":42,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152382"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152382","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}